Susquehanna International Group, LLP Ardelyx, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$5.28 - $7.57 $340,032 - $487,508	-64,400 Reduced 13.07%	428,500 $2.95 Million
Q2 2024 Aug 15, 2024	SELL	$5.89 - $9.31 $1.63 Million - $2.58 Million	-277,400 Reduced 36.01%	492,900 $3.65 Million
Q1 2024 May 07, 2024	BUY	$6.05 - $9.74 $304,315 - $489,922	50,300 Added 6.99%	770,300 $5.62 Million
Q4 2023 Feb 14, 2024	SELL	$3.29 - $6.64 $993,909 - $2.01 Million	-302,100 Reduced 29.56%	720,000 $4.46 Million
Q3 2023 Nov 14, 2023	BUY	$3.3 - $4.83 $557,040 - $815,304	168,800 Added 19.78%	1,022,100 $4.17 Million
Q2 2023 Aug 11, 2023	BUY	$3.23 - $4.95 $408,595 - $626,175	126,500 Added 17.41%	853,300 $2.89 Million
Q1 2023 May 16, 2023	SELL	$2.68 - $4.79 $368,768 - $659,104	-137,600 Reduced 15.92%	726,800 $3.48 Million
Q4 2022 Feb 14, 2023	BUY	$1.22 - $2.85 $113,216 - $264,480	92,800 Added 12.03%	864,400 $2.46 Million
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.44 $190,452 - $464,832	322,800 Added 71.93%	771,600 $918,000

218

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $806M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.